CEL-SCI Advances Multikine Commercialization Efforts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
"During the fiscal second quarter, we made significant progress advancing Multikine toward potential commercialization and regulatory approval in multiple markets," stated CEL-SCI CEO Geert Kersten. "Our strategic partnership with Amarox represents an important milestone for CEL-SCI, providing a pathway to potential early commercialization and revenue generation for Multikine in Saudi Arabia through the SFDA's Breakthrough Medicine Designation process as well as potential market access in the GCC countries. At the same time, we are starting efforts to initiate patient enrollment in our pivotal U.S. FDA Confirmatory Registration Study later this summer/fall. We believe the study's design, which allows for rapid assessment of pre-surgical tumor response following a short course of Multikine treatment, may provide an opportunity to pursue accelerated approval in the U.S. With strengthening financial support, continued management investment in the Company, and increasing international interest in Multikine, we believe CEL-SCI is entering an inflection point."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVM
About CVM
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cel-Sci Plans Fundraising to Advance Cancer Drug Development
- Fundraising Initiative: Cel-Sci plans to raise approximately $2.5 million by offering 2.5 million shares at $1 each, aimed at advancing the development of its Multikine cancer drug, indicating the company's ongoing commitment to cancer treatment innovation.
- Stock Price Decline: Following the announcement of a second stock offering, Cel-Sci's shares fell over 7% in pre-market trading, marking the fifth consecutive day of decline, reflecting market concerns regarding the company's fundraising strategy.
- Clinical Trial Success: Multikine demonstrated significant efficacy in Phase 3 trials, increasing the five-year survival rate from 45% to 73% and reducing the risk of death to 27%, establishing a strong foundation for its future market introduction.
- Strategic Partnership: Cel-Sci has partnered with Amarox to secure regulatory approval and commercialize Multikine in Saudi Arabia, with potential expansion to other Gulf countries, showcasing the company's growth potential in international markets.
See More
CEL-SCI Corporation Prices Public Offering at $1.00 per Share
- Offering Size: CEL-SCI Corporation is pricing its public offering of 2.5 million shares at $1.00 each, expecting to raise $2.5 million in gross proceeds, although this amount will be reduced by placement agent fees and other expenses, potentially impacting liquidity.
- Use of Proceeds: The funds raised will be allocated to advance the clinical development of its lead investigational immunotherapy, Multikine, while also supporting general corporate purposes and working capital needs, indicating the company's commitment to future product development.
- Market Reaction: Following the public offering announcement, CEL-SCI's stock slid 7.4% in premarket trading, reflecting a cautious market sentiment regarding the financing, which may affect investor confidence.
- Underwriting Arrangement: ThinkEquity is serving as the sole placement agent for the transaction, and this choice may influence the flexibility and cost of future financing efforts.
See More
CEL-SCI Corporation Prices 2.5 Million Share Offering at $1 Each
- Funding Size: CEL-SCI Corporation has announced a best-efforts offering of 2.5 million shares at $1 each, expecting gross proceeds of $2.5 million, which will support the ongoing development of Multikine and other corporate purposes.
- Offering Timeline: The offering is expected to close on June 16, 2026, subject to customary closing conditions, providing a clear timeline for the company to secure necessary funding.
- Underwriter Role: ThinkEquity is acting as the sole placement agent for this offering, which will help ensure the smooth execution of the capital raise and enhance market confidence in CEL-SCI's financial strategy.
- Regulatory Compliance: The offering will be conducted under a shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements and providing investors with transparency and legal protections.
See More
Saudi Arabia Emerges as a Global Biotech Investment Hub
- Strategic Partnership: The signing of the agreement between CEL-SCI and Amarox at the 2026 BIO International Convention marks a significant step toward the commercialization of Multikine® in Saudi Arabia, expected to drive rapid growth in the country's biotech market.
- Market Potential: The Saudi immunotherapy market is projected to reach $2.7 billion by 2033, highlighting the substantial investment potential in cancer treatment and attracting international investors' attention.
- Strong Government Support: The Saudi Ministry of Health's role as an official sponsor of BIO 2026 underscores the importance of biotechnology as a strategic priority, reflecting the government's commitment to supporting the biotech sector.
- Regional Expansion Opportunities: Amarox's exclusive commercial distribution rights in Saudi Arabia and the option to expand into Gulf Cooperation Council countries indicate that the collaboration between CEL-SCI and Amarox will lay the groundwork for future regional market growth.
See More
Cel-Sci Releases Q2 Financial Results
- Financial Performance: Cel-Sci reported a Q2 GAAP EPS of -$1.35, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Flow Status: As of the reporting period, Cel-Sci had cash and cash equivalents of $1.89 million, suggesting tight liquidity that may impact future operations and R&D investments.
- Historical Performance Comparison: Compared to the previous quarter, Cel-Sci's GAAP EPS deteriorated from -$0.68 to -$1.35, raising concerns among investors regarding the company's future outlook and financial health.
- Financial Transparency: The financial information provided by Cel-Sci highlights challenges in sustaining operations, prompting investors to closely monitor the company's subsequent financial strategies and market responses.
See More
CEL-SCI Prices Public Offering of 6M Shares at $1.20 Each
- Offering Details: CEL-SCI has priced a public offering of 6 million shares of common stock at $1.20 per share, with total gross proceeds expected to be approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital in the market.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, highlighting the company's strategic focus on its core product and future growth initiatives.
- Market Reaction: Following the announcement of the public offering, CEL-SCI's stock price declined about 10% during pre-market trading on Tuesday, reflecting market concerns regarding the financing and fluctuations in investor sentiment.
- Financial Performance Overview: CEL-SCI reported a GAAP EPS of -$0.68, indicating ongoing challenges in profitability, which may affect investor confidence in the company's future development.
See More
Cel-Sci Plans Fundraising to Advance Cancer Drug Development
- Fundraising Initiative: Cel-Sci plans to raise approximately $2.5 million by offering 2.5 million shares at $1 each, aimed at advancing the development of its Multikine cancer drug, indicating the company's ongoing commitment to cancer treatment innovation.
- Stock Price Decline: Following the announcement of a second stock offering, Cel-Sci's shares fell over 7% in pre-market trading, marking the fifth consecutive day of decline, reflecting market concerns regarding the company's fundraising strategy.
- Clinical Trial Success: Multikine demonstrated significant efficacy in Phase 3 trials, increasing the five-year survival rate from 45% to 73% and reducing the risk of death to 27%, establishing a strong foundation for its future market introduction.
- Strategic Partnership: Cel-Sci has partnered with Amarox to secure regulatory approval and commercialize Multikine in Saudi Arabia, with potential expansion to other Gulf countries, showcasing the company's growth potential in international markets.
See More
CEL-SCI Corporation Prices Public Offering at $1.00 per Share
- Offering Size: CEL-SCI Corporation is pricing its public offering of 2.5 million shares at $1.00 each, expecting to raise $2.5 million in gross proceeds, although this amount will be reduced by placement agent fees and other expenses, potentially impacting liquidity.
- Use of Proceeds: The funds raised will be allocated to advance the clinical development of its lead investigational immunotherapy, Multikine, while also supporting general corporate purposes and working capital needs, indicating the company's commitment to future product development.
- Market Reaction: Following the public offering announcement, CEL-SCI's stock slid 7.4% in premarket trading, reflecting a cautious market sentiment regarding the financing, which may affect investor confidence.
- Underwriting Arrangement: ThinkEquity is serving as the sole placement agent for the transaction, and this choice may influence the flexibility and cost of future financing efforts.
See More
CEL-SCI Corporation Prices 2.5 Million Share Offering at $1 Each
- Funding Size: CEL-SCI Corporation has announced a best-efforts offering of 2.5 million shares at $1 each, expecting gross proceeds of $2.5 million, which will support the ongoing development of Multikine and other corporate purposes.
- Offering Timeline: The offering is expected to close on June 16, 2026, subject to customary closing conditions, providing a clear timeline for the company to secure necessary funding.
- Underwriter Role: ThinkEquity is acting as the sole placement agent for this offering, which will help ensure the smooth execution of the capital raise and enhance market confidence in CEL-SCI's financial strategy.
- Regulatory Compliance: The offering will be conducted under a shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements and providing investors with transparency and legal protections.
See More
Saudi Arabia Emerges as a Global Biotech Investment Hub
- Strategic Partnership: The signing of the agreement between CEL-SCI and Amarox at the 2026 BIO International Convention marks a significant step toward the commercialization of Multikine® in Saudi Arabia, expected to drive rapid growth in the country's biotech market.
- Market Potential: The Saudi immunotherapy market is projected to reach $2.7 billion by 2033, highlighting the substantial investment potential in cancer treatment and attracting international investors' attention.
- Strong Government Support: The Saudi Ministry of Health's role as an official sponsor of BIO 2026 underscores the importance of biotechnology as a strategic priority, reflecting the government's commitment to supporting the biotech sector.
- Regional Expansion Opportunities: Amarox's exclusive commercial distribution rights in Saudi Arabia and the option to expand into Gulf Cooperation Council countries indicate that the collaboration between CEL-SCI and Amarox will lay the groundwork for future regional market growth.
See More
Cel-Sci Releases Q2 Financial Results
- Financial Performance: Cel-Sci reported a Q2 GAAP EPS of -$1.35, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Flow Status: As of the reporting period, Cel-Sci had cash and cash equivalents of $1.89 million, suggesting tight liquidity that may impact future operations and R&D investments.
- Historical Performance Comparison: Compared to the previous quarter, Cel-Sci's GAAP EPS deteriorated from -$0.68 to -$1.35, raising concerns among investors regarding the company's future outlook and financial health.
- Financial Transparency: The financial information provided by Cel-Sci highlights challenges in sustaining operations, prompting investors to closely monitor the company's subsequent financial strategies and market responses.
See More
CEL-SCI Prices Public Offering of 6M Shares at $1.20 Each
- Offering Details: CEL-SCI has priced a public offering of 6 million shares of common stock at $1.20 per share, with total gross proceeds expected to be approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital in the market.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, highlighting the company's strategic focus on its core product and future growth initiatives.
- Market Reaction: Following the announcement of the public offering, CEL-SCI's stock price declined about 10% during pre-market trading on Tuesday, reflecting market concerns regarding the financing and fluctuations in investor sentiment.
- Financial Performance Overview: CEL-SCI reported a GAAP EPS of -$0.68, indicating ongoing challenges in profitability, which may affect investor confidence in the company's future development.
See More
